Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.50    0.50 (0.78%)
Bid:
64.00
Ask:
65.00
Spread: 1.00 (1.563%)
Market Cap: £15.71m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Close of US Placing

5 Jan 2015 07:00

RNS Number : 2238B
MyCelx Technologies Corporation
05 January 2015
 



Not for release, publication or distribution directly or indirectly, in whole or in part, in or into or from the United States of America, its territories and possessions, any state of the United States, and the District of Columbia (collectively, the "United States"), Canada, Australia, the Republic of South Africa, the Republic of Ireland or Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

 

This press release does not constitute or form a part of, and should not be construed as, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities in MYCELX Technologies Corporation ("MYCELX" or the "Company").

 

THE COMPANY'S COMMON SHARES HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT") OR ANY STATE SECURITIES LAWS (THE "STATE ACTS") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO OR FOR THE ACCOUNT OR BENEFIT OF US PERSONS UNLESS THE SECURITIES ARE REGISTERED UNDER THE US SECURITIES ACT AND ANY APPLICABLE STATE ACTS, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE US SECURITIES ACT AND ANY APPLICABLE STATE ACTS IS AVAILABLE. HEDGING TRANSACTIONS INVOLVING THE COMPANY'S COMMON SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE US SECURITIES ACT.

 

MYCELX Technologies Corporation

 

("MYCELX" or the "Company") (AIM: MYX)

5 January 2015

 

Close of US Placing

 

Further to the announcement of the 2nd December 2014, MYCELX Technologies Corporation (AIM: MYX) today announces the second closing of the US private placement (the "US Placing") of shares of common stock of US$0.025 par value ("Common Shares"), in accordance with Regulation D of the US Securities Act of 1933, as amended ("Regulation D"), on 31 December 2014. At the US Placing's second closing the Company has received commitments to subscribe for 78,977 Common Shares at a price of US$2.35 (150 pence) per new share raising US$185,596, in addition to the commitments to subscribe for 468,773 Common Shares raising $1,101,617 at a price of US$2.35 (150 pence) per new share at the time of the first closing on the 9th December 2014.

 

Separately, the Company recently completed a UK Placing of 4,826,296 new shares of common stock of US$0.025 par value each (the "UK Placing Shares" and, together with the US Placing, the "Placings") with UK institutional investors at a price of 150 pence per new share (the "Placing Price") raising £7.2m (approximately £6.9m net of expenses).

 

The proceeds of the US and UK Placings will be used to fund investment in the fast-to-market lease fleet, to strengthen the balance sheet and for general working capital purposes. The Company sees clear operational advantages of an expanded lease equipment inventory. This allows the Company to mobilise three standard-sized systems for quick response, enabling the Company to accelerate the conversion of opportunities in key geographic regions.

 

This will also enable the Company to participate in more trials, thereby eliminating the need to prioritise trial opportunities and allowing forward deployment of lease equipment in multiple locations (e.g. Houston, MENA, Canada and India).

 

 

 

 

Connie Mixon, CEO of MYCELX, commented:

 

"We are delighted to have successfully completed the US Placing. The funds raised from the US and UK Placings will allow us to continue to drive growth and invest in our fast-to-market lease program."

 

Dealing by Director

 

In addition to the the revised participation of the Directors in Common Shares under the first closing of the US Placing and announced on 10 December 2014, the Company announces that S Griffith, a director of the Company, has subscribed for an additional 873 Common Shares in the second closing of the US Placing at US$2.35 (150 pence) per share, as set out below:

 

Director

Aggregate value of Common Shares to be acquired under the US Placing (US$)

Number of Common Shares initially acquired under the US Placing as announced on 2 December 2014

Number of additional Common Shares acquired under the US Placing as a result of the US placing price adjustment

Total number of Common Shares acquired in the second closing

Total number of Common Shares acquired under the US Placing

Resulting holding of Common Shares as % of enlarged issued share capital

S Griffith

$240,000

60,000

42,127

873

103,000

0.55%

 

 

Application for Admission

 

Application has been made to the London Stock Exchange (the "Exchange") for the new Common Shares issued under the second closing of the US Placing (the "US Placing Shares") to be admitted to trading on AIM. It is expected that admission of the US Placing Shares to trading on AIM ("Admission") will become effective, and dealings in the Shares will commence on AIM, at 8.00am on 9 January 2015.

 

On Admission, the Company will have in issue a total of 18,631,780 Common Shares.

 

For further information please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO

Mark Clark, CFO +1 888 306 6843

 

Numis Securities Limited

Corporate Finance

Stuart Skinner

Nathaniel Janks +44 20 7260 1000

 

Corporate Broking

James Black

Ben Stoop +44 20 7260 1000

Bell Pottinger

Nick Lambert

Henry Lerwill +44 20 3772 2500

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEZMGGMZDLGKZZ
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.